Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership

Core Insights - Dyadic International, Inc. has entered into a development and commercialization partnership with Proliant Health and Biologicals to enhance their product offerings in the animal-free protein market [1][6][10] - The partnership aims to leverage Dyadic's microbial protein production technology to develop recombinant protein products that can compete with traditional proteins in terms of value and quality [2][6] Company Overview - Dyadic International is a biotechnology company focused on innovative microbial protein production platforms to meet the demand for cost-effective recombinant proteins across various sectors, including industrial, animal health, and human health [7][11] - Proliant Health and Biologicals is a leading supplier of purified proteins, committed to high standards of consistency, traceability, and quality in the market [12] Partnership Details - The agreement includes an upfront milestone payment of $1.5 million to Dyadic, along with a share of profits from the sale of animal-free recombinant albumin products produced using Dyadic's technology [10] - The initial focus of the partnership will be on the commercialization of recombinant human serum albumin products, with the first product expected to launch in the first half of 2025 [10]